EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC

Jun Miyakoshi, Tatsuya Yoshida, Yuji Uehara, Yuki Takeyasu, Masayuki Shirasawa, Akito Fukuda, Jumpei Kashima, Shogo Kumagai, Hidehito Horinouchi, Hanako Ono, Kouya Shiraishi, Takashi Kohno und 9 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2025-012880 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Jun Miyakoshi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, B7-H1 Antigen, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Compared with conventional chemotherapy, pembrolizumab-based chemoimmunotherapy (Pembro) and nivolumab plus ipilimumab with or without two cycles of platinum-doublet chemotherapy (Nivo+Ipi) improve survival in advanced non-small cell lung cancer (NSCLC). However, biomarkers for selecting optimal immunotherapy remain unclear. This study aimed to assess whether programmed cell death-ligand 1 (PD-L1) expression on tumor and immune cells (ICs) can guide first-line immunotherapy in advanced NSCLC.

Methods

This multicenter, observational study retrospectively reviewed patients with NSCLC treated with first-line Pembro or Nivo+Ipi who had evaluable PD-L1 expression on tumor (Tumor Proportion Score (TPS), 22C3) and ICs score (SP142). In addition, whole-exome and RNA sequencing were performed on treatment-naïve NSCLCs with available PD-L1 expression status by both assays.

Results

Between 2019 and 2023, 198 patients were included (Pembro/Nivo+Ipi: 137/61). In the Pembro cohort, patients with high TPS (≥ 50%) had significantly longer progression-free survival (PFS) than those with low TPS (< 50%) (median PFS (mPFS, months): 8.1 vs 7.1; p=0.02), while IC score was not predictive. In the Nivo+Ipi cohort, high IC score (≥1) was associated with longer PFS than low IC score (0) (mPFS: 7.7 vs 2.8; p=0.04), while TPS showed no impact. Among patients with low TPS/high IC scores, Nivo+Ipi achieved longer PFS than Pembro (mPFS: 12.4 vs 6.6; restricted mean survival time (RMST) Nivo+Ipi /RMST Pembro (24 months)=1.5; p=0.049). Multiomics analysis using 152 NSCLC samples showed that tumors with low TPS/high IC scores exhibited an activated tumor immune microenvironment comparable to that of tumors with high TPS. However, these tumors had significantly highest tumor mutation burden (TMB) and regulatory T cell (T reg ) fraction among the PD-L1 phenotypes (median TMB (mut/Mb): 1.6 in tumors with low TPS/low IC score, 18.2 in low TPS/high IC score, and 1.9 in high TPS/any IC score; median T reg fraction (×10 −2 ]: 0.0, 0.2, and 0.0, respectively), supporting a potential benefit of cytotoxic T-lymphocyte-associated antigen 4 blockade in addition to programmed cell death protein 1 (PD-1)/PD-L1 inhibition in this subgroup.

Conclusions

Patients with NSCLC and low TPS/high IC scores may benefit more from Nivo+Ipi than from Pembro due to distinct genomic and immunological features, including high TMB and T reg fraction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungB7-H1 AntigenLung NeoplasmsBiomarkers, TumorImmunotherapyImmune Checkpoint InhibitorsCTLA-4 AntigenHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultPhenotypeAged, 80 and over

Stichwörter der Autor:innen

BiomarkerImmune Checkpoint InhibitorLung CancerTumor microenvironment - TMETumor mutation burden - TMB

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, TumorImmune Checkpoint InhibitorsCTLA-4 AntigenCTLA4 protein, human

Autor:innen und Institutionen

  • Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
  • Department of Respiratory Medicine, Chiba University, Chiba, Chiba, Japan.
  • Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
  • Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan tatyoshi@ncc.go.jp.
  • Department of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
  • Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan.

Zitieren

APA

Miyakoshi, J., Yoshida, T., Uehara, Y., Takeyasu, Y., Shirasawa, M., Fukuda, A., Kashima, J., Kumagai, S., Horinouchi, H., Ono, H., Shiraishi, K., Kohno, T., Kondo, S., Goto, Y., Yamamoto, N., Yatabe, Y., Hosomi, Y., Kurata, T., Naoki, K., …, & Ohe, Y. (2025). PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012880

Vancouver

Miyakoshi J, Yoshida T, Uehara Y, Takeyasu Y, Shirasawa M, Fukuda A, et al. PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-012880

BibTeX
@article{Miyakoshi2025,
  author = {Miyakoshi, Jun and Yoshida, Tatsuya and Uehara, Yuji and Takeyasu, Yuki and Shirasawa, Masayuki and Fukuda, Akito and Kashima, Jumpei and Kumagai, Shogo and Horinouchi, Hidehito and Ono, Hanako and Shiraishi, Kouya and Kohno, Takashi and Kondo, Shunsuke and Goto, Yasushi and Yamamoto, Noboru and Yatabe, Yasushi and Hosomi, Yukio and Kurata, Takayasu and Naoki, Katsuhiko and Suzuki, Takuji and Ohe, Yuichiro},
  title = {PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-012880}
}
Kostenlos starten →